130 related articles for article (PubMed ID: 11678309)
21. Pharmacological inhibition of VIP signaling enhances antiviral immunity and improves survival in murine cytomegalovirus-infected allogeneic bone marrow transplant recipients.
Li JM; Hossain MS; Southerland L; Waller EK
Blood; 2013 Mar; 121(12):2347-51. PubMed ID: 23325838
[TBL] [Abstract][Full Text] [Related]
22. VIP receptor antagonists inhibit mammary carcinogenesis in C3(1)SV40T antigen mice.
Moody TW; Dudek J; Zakowicz H; Walters J; Jensen RT; Petricoin E; Couldrey C; Green JE
Life Sci; 2004 Jan; 74(11):1345-57. PubMed ID: 14706566
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of human neuroblastoma growth by a specific VIP antagonist.
Lilling G; Wollman Y; Goldstein MN; Rubinraut S; Fridkin M; Brenneman DE; Gozes I
J Mol Neurosci; 1994-1995; 5(4):231-9. PubMed ID: 7577366
[TBL] [Abstract][Full Text] [Related]
24. Vasoactive intestinal peptide receptors: a molecular target in breast and lung cancer.
Moody TW; Gozes I
Curr Pharm Des; 2007; 13(11):1099-104. PubMed ID: 17430173
[TBL] [Abstract][Full Text] [Related]
25. Vasoactive intestinal peptide-camptothecin conjugates inhibit the proliferation of breast cancer cells.
Moody TW; Mantey SA; Fuselier JA; Coy DH; Jensen RT
Peptides; 2007 Sep; 28(9):1883-90. PubMed ID: 17580098
[TBL] [Abstract][Full Text] [Related]
26. Effects of the vasoactive intestinal peptide (VIP) and related peptides on glioblastoma cell growth in vitro.
Dufes C; Alleaume C; Montoni A; Olivier JC; Muller JM
J Mol Neurosci; 2003; 21(2):91-102. PubMed ID: 14593209
[TBL] [Abstract][Full Text] [Related]
27. Characterization of vasoactive intestinal peptide receptors on rat alveolar macrophages.
Sakakibara H; Shima K; Said SI
Am J Physiol; 1994 Sep; 267(3 Pt 1):L256-62. PubMed ID: 7943252
[TBL] [Abstract][Full Text] [Related]
28. Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide receptor chimeras reveal domains that determine specificity of vasoactive intestinal polypeptide binding and activation.
Hashimoto H; Ogawa N; Hagihara N; Yamamoto K; Imanishi K; Nogi H; Nishino A; Fujita T; Matsuda T; Nagata S; Baba A
Mol Pharmacol; 1997 Jul; 52(1):128-35. PubMed ID: 9224822
[TBL] [Abstract][Full Text] [Related]
29. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis.
Zawilska JB; Niewiadomski P; Nowak JZ
Gen Comp Endocrinol; 2004 Jun; 137(2):187-95. PubMed ID: 15158130
[TBL] [Abstract][Full Text] [Related]
30. The development of VIP-ellipticine conjugates.
Moody TW; Czerwinski G; Tarasova NI; Moody DL; Michejda CJ
Regul Pept; 2004 Dec; 123(1-3):187-92. PubMed ID: 15518911
[TBL] [Abstract][Full Text] [Related]
31. Vasoactive intestinal peptide (VIP) inhibits human renal cell carcinoma proliferation.
Vacas E; Fernández-Martínez AB; Bajo AM; Sánchez-Chapado M; Schally AV; Prieto JC; Carmena MJ
Biochim Biophys Acta; 2012 Oct; 1823(10):1676-85. PubMed ID: 22728770
[TBL] [Abstract][Full Text] [Related]
32. Characterization of VIP receptor-effector system antagonists in rat and mouse peritoneal macrophages.
Pozo D; Montilla ML; Guerrero JM; Calvo JR
Eur J Pharmacol; 1997 Mar; 321(3):379-86. PubMed ID: 9085051
[TBL] [Abstract][Full Text] [Related]
33. Human H9 cells proliferation is differently controlled by vasoactive intestinal peptide or peptide histidine methionine: implication of a GTP-insensitive form of VPAC1 receptor.
Goursaud S; Pineau N; Becq-Giraudon L; Gressens P; Muller JM; Janet T
J Neuroimmunol; 2005 Jan; 158(1-2):94-105. PubMed ID: 15589042
[TBL] [Abstract][Full Text] [Related]
34. Effects of vasoactive intestinal peptide on adenosine 3',5'-monophosphate, ornithine decarboxylase, and cell growth in a human colon cell line.
Yu D; Seitz PK; Selvanayagam P; Rajaraman S; Townsend CM; Cooper CW
Endocrinology; 1992 Sep; 131(3):1188-94. PubMed ID: 1324153
[TBL] [Abstract][Full Text] [Related]
35. The autocrine regulatory effect of vasoactive intestinal peptide on the growth of human pancreatic carcinoma cells.
Chen Y; Chen Q; Lu G; Fan Z; Zhong S
Chin Med Sci J; 1994 Dec; 9(4):215-9. PubMed ID: 7718859
[TBL] [Abstract][Full Text] [Related]
36. The C-terminal part of VIP is important for receptor binding and activation, as evidenced by chimeric constructs of VIP/secretin.
Wulff B; Møller Knudsen S; Adelhorst K; Fahrenkrug J
FEBS Lett; 1997 Aug; 413(3):405-8. PubMed ID: 9303545
[TBL] [Abstract][Full Text] [Related]
37. VIP and breast cancer.
Moody TW; Leyton J; Gozes I; Lang L; Eckelman WC
Ann N Y Acad Sci; 1998 Dec; 865():290-6. PubMed ID: 9928023
[TBL] [Abstract][Full Text] [Related]
38. Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor.
Xia M; Sreedharan SP; Bolin DR; Gaufo GO; Goetzl EJ
J Pharmacol Exp Ther; 1997 May; 281(2):629-33. PubMed ID: 9152366
[TBL] [Abstract][Full Text] [Related]
39. VIP as a trophic factor in the CNS and cancer cells.
Moody TW; Hill JM; Jensen RT
Peptides; 2003 Jan; 24(1):163-77. PubMed ID: 12576099
[TBL] [Abstract][Full Text] [Related]
40. 99mTc-labeled vasoactive intestinal peptide receptor agonist: functional studies.
Pallela VR; Thakur ML; Chakder S; Rattan S
J Nucl Med; 1999 Feb; 40(2):352-60. PubMed ID: 10025846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
